Income Statement
UROGEN PHARMA LTD.
URGN
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY |
|---|---|---|---|---|---|---|---|---|
|
Revenue
|
109.79 | 90.40 | 82.71 | 64.36 | 48.04 | 11.80 | 0.02 | 1.13 |
|
Cost of Revenue
|
12.45 | 8.88 | 9.36 | 7.65 | 5.16 | 1.01 | - | 1.80 |
|
Gross Profit
|
97.34 | 81.52 | 73.35 | 56.70 | 42.89 | 10.79 | 0.02 | -0.68 |
|
Operating Expenses
|
222.20 | 178.30 | 138.89 | 135.74 | 135.18 | 137.53 | 109.50 | 39.57 |
|
Research & Development
|
67.11 | 57.15 | 45.61 | 52.91 | 47.64 | 47.31 | 49.30 | - |
|
Selling, General & Administrative
|
155.10 | 121.15 | 93.27 | 82.84 | 87.54 | 90.22 | 60.20 | 39.57 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - |
|
Operating Income
|
-124.86 | -96.78 | -65.54 | -79.04 | -92.29 | -126.74 | -109.48 | -40.25 |
|
Non-Operating Income
|
-0.67 | -0.23 | 0.84 | 0.07 | 17.08 | -1.63 | -4.33 | 35.29 |
|
Interest Income
|
5.97 | 8.90 | 2.64 | 0.94 | 0.37 | 1.99 | - | - |
|
Interest Expense
|
- | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - | -0.28 | - |
|
Income Before Tax
|
-153.42 | -124.04 | -98.32 | -108.03 | -109.37 | -125.11 | -105.15 | -75.53 |
|
Income Tax Expense
|
0.08 | 2.83 | 3.92 | 1.76 | 1.45 | 3.37 | 0.00 | 0.13 |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - |
|
Net Income
|
-153.49 | -126.87 | -102.24 | -109.78 | -110.82 | -128.48 | -105.15 | -75.66 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY |
|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - |
|
EBITDA
|
-124.56 | -96.45 | -64.73 | -78.12 | -91.46 | -126.32 | -109.18 | -39.83 |
|
Earnings Per Share (Basic)
|
-3.19 | -2.96 | -3.55 | -4.81 | - | - | - | - |
|
Diluted EPS
|
- | - | - | - | - | - | - | - |
|
Weighted Average Shares
|
48.12 | 42.88 | 28.83 | 22.81 | - | - | - | - |
|
Diluted Weighted Avg Shares
|
- | - | - | - | - | - | - | - |
|
Comprehensive Income
|
-153.53 | -126.83 | -102.13 | -109.87 | -111.12 | -128.49 | -104.87 | - |